Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmaDrug Inc. (PHRX) announces that Robert Schwartz has resigned from the board of directors
  • Schwartz has 25 years of healthcare sales and marketing experience dealing with pharmaceuticals, diagnostics, medical devices and equipment, and medical communications
  • PharmaDrug will appoint current board member David Kideckel to Schwartz position on the company’s audit committee
  • Kideckel has over 20 years of combined industry and capital markets experience
  • PharmaDrug Inc. (PHRX) is down 16.67 per cent and is trading at $0.05 per share as of 2:45 p.m. EST

PharmaDrug Inc. (PHRX) has announced the resignation of Robert Schwartz from the board of directors.

Schwartz has 25 years of healthcare sales and marketing experience focused on introducing cost-saving account coverage efficiencies.

He dealt with pharmaceuticals, diagnostics, medical devices and equipment, and medical communications.

Effective immediately, PharmaDrug will appoint current board member David Kideckel to Schwartz’s position on the company’s audit committee.

He has over 20 years of related industry and capital markets experience.

Prior to PharmaDrug, he served as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets.

PharmaDrug is a specialty pharmaceutical company focused on natural medicines such as psychedelics, cannabis and naturally derived approved drugs.

PharmaDrug Inc. (PHRX) is down 16.67 per cent and is trading at $0.05 per share as of 2:45 p.m. EST.

More From The Market Herald
HEXO - CEO, Scott Cooper.

" HEXO (TSX:HEXO) delineates its path forward

HEXO (HEXO) has announced cost-saving initiatives to carry the company into the future.

" Tinley’s (CSE:TNY) makes production announcement, closes first tranche of private placement

The Tinley Beverage Company (TNY) will begin making Green Monké products at its Long Beach facility.
The Market Herald Video

" Psyched Wellness (CSE:PSYC) announces partnership with Vantage Hemp Co.

Psyched Wellness (PSYC) has announced a manufacturing partnership with Vantage Hemp Co.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.